ISPOR Issue Panel: Evolving Approaches to Measuring Benefits in Economic Evaluation

EntityRisk’s Darius Lakdawalla, PhD, will participate as a speaker in this ISPOR Issue Panel exploring whether the Health Economics Methods Advisory (HEMA) recommendations go far enough for global HTA practice.

Upcoming: Let's meet in Philadelphia!

Join EntityRisk and industry leaders for an exclusive forum on value-based pricing, evidence generation, and navigating evolving healthcare landscape. ISPOR Philadelphia, May 17 – 20, 2026. Come visit us in Booth #805.

About EntityRisk

EntityRisk integrates globally renowned health economics and policy expertise with PROVEN™, our advanced modelling software, to predict health outcomes, identify maximum value-based pricing, and substantiate evidence-generation investments.

10 of the Top 20 Biopharma Companies work with EntityRisk to navigate the shifting policy landscape and confidently choose and defend justifiable prices, inform evidence investments, and communicate and win on value.

10 / 20

Top Biopharma Companies

1,300+

Quality Checks

5

ML Modules

Leverage software built by a team with world- class scientific, engineering and industry credentials.